LTF and enterovirus infectious disease: Several investigators have explored potential therapeutics against enterovirus infections, including small molecular inhibitors (e.g., pleconaril that binds VP1) (Ledford et al., 2004), ribavirin (nucleoside analog) (Li et al., 2008), rupintrivir (cysteine-protease inhibitor) (Zhang et al., 2010), siRNA to the virus 3D polymerase (Tan et al., 2007), and lactoferrin (Lin et al., 2002).